To protect your child, their doctor will give them the pneumococcal conjugate vaccine (PCV). "This is a great example of a ...

A large surveillance study suggests that an extra pneumococcal vaccine dose for new care home residents can significantly ...

US FDA accepts for Priority Review the supplemental Biologics License Application for Merck’s Vaxneuvance™ (pneumococcal 15-valent conjugate vaccine) for use in infants and children. News release.

The 20-valent pneumococcal conjugate vaccine may be preferable due to convenience. Over the last decade, there have been several updates to pneumococcal vaccinations in adolescents and adults, ...

Merck announces positive topline results from PNEU-DIRECTION (V114-027) and PNEU-PLAN (V114-024) phase 3 pediatric studies for V114, Merck’s Investigational 15-valent pneumococcal conjugate vaccine.

Merck Announces VAXNEUVANCE™ (Pneumococcal 15-valent Conjugate Vaccine) Met Key Immunogenicity and Safety Endpoints in Phase 3 Pivotal Trial Evaluating Use in Infants, PNEU-PED (V114-029) ...

The pneumococcal conjugate vaccine (PCV) is the first vaccine proven to be effective in reducing the incidence of invasive pneumococcal disease, pneumonia and acute otitis media in children, and ...

A 10-valent pneumococcal conjugate vaccine, PCV, is effective in reducing the number of new cases of likely-bacterial community-acquired pneumonia in infants in Latin America, according to a study ...

The advisors also voted 14-1 to recommend a pneumococcal conjugate vaccine (PCV) for all PCV-naive adults ages 50 and older. Shortly after the ACIP meeting, CDC Director Mandy Cohen, MD, MPH ...

Among the other recommendations, for those 65 and over who have not gotten a pneumococcal conjugate vaccine or who have unknown vaccination histories, it is recommended that they receive 1 PCV15 ...

Children under five years of age, especially those aged two years or under, face a high risk of pneumococcal disease, which ...